<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant sodium citrate (Regional citrate anticoagulant): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant sodium citrate (Regional citrate anticoagulant): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anticoagulant sodium citrate (Regional citrate anticoagulant): Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50812601"><span class="drugH1">Brand Names: US</span>
<ul>
<li>TriCitrasol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50812605"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant</li></ul></div>
<div class="block doa drugH1Div" id="F53328702"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b>
<b>4% trisodium citrate has a sodium content of 408 mmol/L. </b>To avoid severe hypernatremia, protocols typically employ lower sodium dialysate and/or replacement fluids and titrate accordingly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24993448','lexi-content-ref-19384210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24993448','lexi-content-ref-19384210'])">Ref</a></span>). Refer to institutional protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5094b0ba-1589-48bf-9983-2ddea6e28ec9">Regional anticoagulation for continuous renal replacement therapy circuit</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Regional anticoagulation for continuous renal replacement therapy circuit (off-label use): Note:</b> Citrate solution must only be prescribed and administered by trained personnel, as standardized (and often specialized) dialysate and/or replacement fluids and titration and monitoring protocols are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24993448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24993448'])">Ref</a></span>). Citrate solution is administered through the inflow (prefilter or “arterial”) limb of the extracorporeal CRRT circuit, <b>not</b> administered directly to the patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.2018'])">Ref</a></span>). <b>Safety: </b>According to the manufacturer, use is contraindicated in patients likely to have impaired citrate clearance (eg, acute liver failure with transaminases &gt;1,000 units/L); however, if necessary, may be used with close monitoring and appropriate adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.2018','lexi-content-ref-29324487','lexi-content-ref-26415638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.2018','lexi-content-ref-29324487','lexi-content-ref-26415638'])">Ref</a></span>). When regional citrate anticoagulation is utilized, calcium is lost in the dialysis effluent in the form of citrate-calcium complexes. Calcium repletion must be administered to avoid hypocalcemia. Calcium may be infused at the end of the dialysis circuit or IV through a separate central line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.2018','lexi-content-ref-29151020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.2018','lexi-content-ref-29151020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial infusion rate (<b>in mL/hour</b>):</i>
<b>Intracircuit:</b> Use a 4% trisodium citrate dihydrate solution: <b>Approximate usual initial infusion rate:</b> ~1 to 1.5 times the blood flow rate; for example, if blood flow rate is 100 to 200 mL/minute, start infusion at 100 to 300 mL/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18272829','lexi-content-ref-Davenport.2018','lexi-content-ref-24993448','lexi-content-ref-19384210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18272829','lexi-content-ref-Davenport.2018','lexi-content-ref-24993448','lexi-content-ref-19384210'])">Ref</a></span>). Optimal 4% trisodium regimens have not been identified; refer to institutional protocols as variations exist. Adjustment of 4% trisodium citrate and calcium infusion rates is dependent on established protocols and ionized calcium concentrations.</p>
<p style="text-indent:-2em;margin-left:8em;">CRRT calcium: Monitor ionized calcium concentrations in outflow (postfilter) limb of the CRRT circuit; maintain CRRT circuit iCa between 1 to 1.4 mg/dL (0.25 to 0.35 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18272829','lexi-content-ref-10793012','lexi-content-ref-14600809','lexi-content-ref-25881975','lexi-content-ref-33095849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18272829','lexi-content-ref-10793012','lexi-content-ref-14600809','lexi-content-ref-25881975','lexi-content-ref-33095849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Serum calcium: Monitor systemic iCa concentration peripherally (drawn directly from the patient) and maintain systemic iCa between 3.6 to 4.8 mg/dL (0.9 to 1.2 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18272829','lexi-content-ref-25853591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18272829','lexi-content-ref-25853591'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F50795130"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, chest pressure, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills, paresthesia, tingling in the lips, tingling of extremities</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Stomach cramps</p></div>
<div class="block coi drugH1Div" id="F50812622"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Do not administer to a patient by direct IV infusion.</p></div>
<div class="block war drugH1Div" id="F50812623"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with liver impairment. Citrate is partially metabolized by the liver and may accumulate with hepatic impairment leading to toxicity. Considered contraindicated in patients with acute liver failure and blood transaminase values &gt;1,000 units/L; however, if necessary, may be used with close monitoring and appropriate adjustments (Davenport 2021; Meersch 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shock states: Use with caution in patients with shock and hypoperfusion; may accumulate with hypoperfusion/shock states leading to toxicity. Considered contraindicated in patients with cardiogenic shock and blood lactate concentrations &gt;8 mmol/L (Davenport 2021).</p></div>
<div class="block foc drugH1Div" id="F50812630"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, In Vitro: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TriCitrasol: 46.7% (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, In Vitro: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (250 mL, 500 mL)</p></div>
<div class="block geq drugH1Div" id="F50812604"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F51083820"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (TriCitrasol In Vitro)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">46.7% (per mL): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Anticoagulant Sodium Citrate In Vitro)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872336"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, In Vitro: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, In Vitro: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (250 mL)</p></div>
<div class="block use drugH1Div" id="F50812621"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticoagulant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Concentrate (triCitrasol): Anticoagulant used in granulocytapheresis procedures</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Anticoagulant for use with cytapheresis device only</p></div>
<div class="block off-label drugH1Div" id="F53328701"><span class="drugH1">Use: Off-Label: Adult</span><p>Regional anticoagulation for continuous renal replacement therapy circuit</p></div>
<div class="block mst drugH1Div" id="F50812610"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Anticoagulant sodium citrate may be confused with anticoagulant citrate dextrose</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50815311"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50815308"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block mop drugH1Div" id="F53328703"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">When used for regional anticoagulation of the CRRT circuit: Monitor serum electrolytes ~15 minutes and 1 hour after starting CRRT, then at least every 6 hours for CRRT; particularly monitor iCa, sodium, potassium, chloride, magnesium, and bicarbonate to avoid metabolic abnormalities; acid-base balance; anion gap; for CRRT monitor total body calcium at least once daily to calculate the calcium ratio (total calcium/iCa) (calcium ratio may indicate citrate toxicity if &gt;2.1); monitoring post-filter iCa may be beneficial to ensure adequate anticoagulation of the dialysis circuit (Davenport 2021; KDIGO 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Citrate accumulation may be managed by decreasing the blood flow rate (which decreases citrate requirements), increasing the dialysate rate (CVVHD) or the filtration rate (CVVH) to increase removal, or decreasing the targeted citrate concentration within the filter (Schneider 2017).</p></div>
<div class="block pha drugH1Div" id="F53346494"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Citrate ions induce anticoagulation by chelating free ionized calcium, making it unavailable for use in the coagulation system.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58214869"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Natrium citricum</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trav sodium citrate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Natrium citricum</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Natrium citricum</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Natrium citricum</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Natrium citricum</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Natrium citricum</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Anticoagulant.1">
<a name="Anticoagulant.1"></a>Anticoagulant Sodium Citrate 4% w/v solution, USP [prescribing information]. Union, SC: CSL Plasma Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17918147">
<a name="17918147"></a>Betjes MG, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. <i>J Nephrol</i>. 2007;20(5):602-608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/17918147/pubmed" id="17918147" target="_blank">17918147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18272829">
<a name="18272829"></a>Clark JA, Schulman G, Golper TA. Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. <i>Clin J Am Soc Nephrol. </i>2008;3(3): 736-742. doi: 10.2215/CJN.03460807.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/18272829/pubmed" id="18272829" target="_blank">18272829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Davenport.2018">
<a name="Davenport.2018"></a>Davenport A. Anticoagulation for continuous renal replacement therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25853591">
<a name="25853591"></a>Gattas DJ, Rajbhandari D, Bradford C, et al. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. <i>Crit Care Med</i>. 2015;43(8):1622-1629. doi: 10.1097/CCM.0000000000001004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/25853591/pubmed" id="25853591" target="_blank">25853591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20876598">
<a name="20876598"></a>Hetzel GR, Schmitz M, Wissing H, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. <i>Nephrol Dial Transplant. </i>2011;26(1):232-239. doi: 10.1093/ndt/gfq575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/20876598/pubmed" id="20876598" target="_blank">20876598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018916">
<a name="25018916"></a>Kellum JA, Aspelin P, Barsoum RS, et al. KDIGO clinical practice guideline for acute kidney injury. <i>Kidney Int Suppl. </i>2012;2(1):8-12. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf. doi: 10.1038/kisup.2012.7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/25018916/pubmed" id="25018916" target="_blank">25018916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10793012">
<a name="10793012"></a>Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. <i>Am J Kidney Dis</i>. 2000;35(5):802-811.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/10793012/pubmed" id="10793012" target="_blank">10793012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15882280">
<a name="15882280"></a>Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. <i>Kidney Int.</i> 2005;67(6):2361-2367. doi: 10.1111/j.1523-1755.2005.00342.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/15882280/pubmed" id="15882280" target="_blank">15882280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29324487">
<a name="29324487"></a>Meersch M, Zarbock A. Renal replacement therapy in critically ill patients: who, when, why, and how. <i>Curr Opin Anaesthesiol</i>. 2018;31(2):151-157. doi:10.1097/ACO.0000000000000564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/29324487/pubmed" id="29324487" target="_blank">29324487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12608553">
<a name="12608553"></a>Mitchell A, Daul AE, Beiderlinden M, et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD).<i> Clin Nephrol</i>. 2003;59(2):106-114. doi: 10.5414/cnp59106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/12608553/pubmed" id="12608553" target="_blank">12608553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14600809">
<a name="14600809"></a>Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. <i>Intensive Care Med.</i> 2004;30(2):260-265. doi: 10.1007/s00134-003-2047-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/14600809/pubmed" id="14600809" target="_blank">14600809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24993448">
<a name="24993448"></a>Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. <i>Clin J Am Soc Nephrol</i>. 2014;9(12):2173-2188. doi:10.2215/CJN.01280214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/24993448/pubmed" id="24993448" target="_blank">24993448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19384210">
<a name="19384210"></a>Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. <i>Crit Care Med</i>. 2009;37(6):2018-2024. doi:10.1097/CCM.0b013e3181a00a92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/19384210/pubmed" id="19384210" target="_blank">19384210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15361702">
<a name="15361702"></a>Morgera S, Scholle C, Melzer C, et al. A simple, safe and effective citrate anticoagulation protocol for the Genius dialysis system in acute renal failure. <i>Nephron Clin Pract.</i> 2004;98(1):c35-c40. doi:10.1159/000079925.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/15361702/pubmed" id="15361702" target="_blank">15361702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19114912">
<a name="19114912"></a>Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. <i>Crit Care Med.</i> 2009;37(2):545–552. doi: 10.1097/CCM.0b013e3181953c5e.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/19114912/pubmed" id="19114912" target="_blank">19114912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25128022">
<a name="25128022"></a>Schilder L, Nurmohamed SA, Bosch FH, et al; CASH study group. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. <i>Crit Care</i>. 2014;18(4):472. doi: 10.1186/s13054-014-0472-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/25128022/pubmed" id="25128022" target="_blank">25128022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29151020">
<a name="29151020"></a>Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? <i>Crit Care</i>. 2017;21(1):281. doi:10.1186/s13054-017-1880-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/29151020/pubmed" id="29151020" target="_blank">29151020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26415638">
<a name="26415638"></a>Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. <i>Crit Care</i>. 2015;19:349. doi: 10.1186/s13054-015-1066-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/26415638/pubmed" id="26415638" target="_blank">26415638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fenwal.1">
<a name="Fenwal.1"></a>Sodium citrate 250 mL and 500 mL [prescribing information]. Lake Zurich, IL: Fenwal Inc; February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25881975">
<a name="25881975"></a>Stucker F, Ponte B, Tataw J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. <i>Crit Care.</i> 2015;19:91. doi: 10.1186/s13054-015-0822-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/25881975/pubmed" id="25881975" target="_blank">25881975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Citra.1">
<a name="Citra.1"></a>triCitrasol (trisodium citrate dihydrate) [prescribing information]. Braintree, MA: Citra Labs; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33095849">
<a name="33095849"></a>Zarbock A, Küllmar M, Kindgen-Milles D, et al; RICH Investigators and the Sepnet Trial Group. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. <i>JAMA</i>. 2020;324(16):1629-1639. doi:10.1001/jama.2020.18618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-sodium-citrate-regional-citrate-anticoagulant-drug-information/abstract-text/33095849/pubmed" id="33095849" target="_blank">33095849</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 115978 Version 36.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
